# SAREPTA THERAPEUTICS, INC. (SRPT) FY2026 YTD Q2 P&L / Income Statement

- Company: SAREPTA THERAPEUTICS, INC. (SRPT)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001193125-26-335003
- Page: https://plicit.ai/financials/srpt/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/srpt-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Revenue categories. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 1,132,054,000 US dollars
- **Total cost and expenses**: 760,330,000 US dollars
- **Operating income (loss)**: 371,724,000 US dollars
- **Other income (expense), net (calculated)**: negative 30,299,000 US dollars
- **(Loss) income before income tax expense (benefit)**: 341,425,000 US dollars
- **Income tax expense (benefit)**: 15,356,000 US dollars
- **Net (loss) income**: 326,069,000 US dollars
- **Products, net**: 659,204,000 US dollars
- **Collaboration and other**: 472,850,000 US dollars
- **Cost of sales (excluding amortization of in-licensed rights)**: 258,153,000 US dollars
- **Research and development**: 245,218,000 US dollars
- **Selling, general and administrative**: 216,551,000 US dollars
- **Litigation contingency charge**: 39,000,000 US dollars
- **Amortization of in-licensed rights**: 1,408,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.